About Rgenta Therapeutics
Rgenta Therapeutics is a clinical-stage biotechnology company that designs oral small-molecule drugs aimed at disease-causing RNA rather than proteins. It mines genomic data to find RNA sites that small molecules can bind, then builds drug-like compounds that modulate the interactions between RNA, the splicing machinery and regulatory proteins. The company's early work targets cancer and neurological disorders where current drugs cannot reach the underlying genetic cause.
Rgenta is based in Woburn, Massachusetts, and was co-founded by chief executive officer Simon Xi and president and chief scientific officer Travis Wager. Its lead drug, RGT-61159, targets the MYB protein and has received orphan drug designation from the FDA for adenoid cystic carcinoma. The company raised a $20 million seed round in 2020 and a $52 million Series A round in 2022, and has formed research collaborations with Lundbeck and GSK.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 19, 2026 | Nov 3, 2026 | $41,852,307of $130.1M target | 9 | $4.6M | Equity, DebtRule 506(b) | Form D ↗ |
| Nov 9, 2021 | Feb 7, 2022 | $8,914,283fully sold | 6 | $1.4M | EquityRule 506(b) | Form D ↗ |
| Jan 21, 2020 | Feb 5, 2020amended Mar 12, 2021 | $10,034,915of $37.9M target | 6 | $1.6M | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Total, three offerings | $60,801,505 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Rounds announced by Rgenta Therapeutics
What the company said publicly about its funding. Announced amounts can differ from Form D figures: an announcement can combine several closings, and some money is raised without a Form D.
| Announced | Round | Amount | Investors | Source |
|---|---|---|---|---|
| Apr 2, 2020 | Seed | $20 million | Boehringer Ingelheim Venture Fund and Matrix Partners China (co-leads) (co-leads), Kaitai Capital and Legend Star Fund | PR Newswire: Rgenta Therapeutics Launches with $20 Million Seed Investment ↗ |
| Nov 29, 2022 | Series A | $52 million | AZ-CICC Healthcare Investment Fund (lead), Korean Investment Partners and Delos Capital (new investors), with existing investors Boehringer Ingelheim Venture Fund, Matrix Partners China, Lilly Asia Venture and Vivo Capital | PR Newswire: Rgenta Therapeutics Raises $52M in Series A Financing ↗ Delos Capital news post ↗ |
Why Investors Backed Rgenta Therapeutics
Rgenta Therapeutics is a clinical-stage biotech that builds oral drugs aimed at RNA instead of proteins. Its lead candidate, RGT-61159, targets a cancer-driving gene called MYB and is moving toward Phase 3 trials. The company has raised money from venture investors and formed deals with Lundbeck and GSK. Backers see its platform as a way to reach disease targets that other drug types cannot touch.
The problem it targets
Many diseases are driven by genes that make proteins doctors cannot block with a small molecule or an antibody. Rgenta says these targets have long been considered undruggable, including MYB in cancer and the PMS1 gene linked to Huntington's disease. Traditional drugs work on proteins, but Rgenta's approach is to act earlier, on the RNA copied from these genes. Repeat expansion diseases such as Huntington's are caused by abnormal gene sequences that current medicines do not address at the source.
What the product does
Rgenta's lead drug, RGT-61159, is an oral small molecule that blocks production of the MYB protein by acting on its RNA. The company is testing it in adenoid cystic carcinoma and colorectal cancer, two cancers where MYB drives tumor growth. A second program targets the PMS1 gene with an oral inhibitor meant to slow repeat expansion in Huntington's disease. The company has also built a related technology, RSwitch, which uses the same chemistry to turn gene and cell therapy transgenes up or down.
Progress so far
The FDA cleared Rgenta's investigational new drug application for RGT-61159 in July 2024, and the company dosed its first patients that October. In September 2025 the FDA granted RGT-61159 orphan drug designation for adenoid cystic carcinoma. Preliminary Phase 1a/b results were presented at the 2026 ASCO meeting. In October 2026, Rgenta completed an end-of-Phase 2 meeting with the FDA and agreed on a Phase 3 trial design. In December 2024 the company also struck a strategic alliance with GSK to develop RNA-targeted splice modulators, following an earlier 2021 collaboration with Lundbeck on neurological targets.
Who backs it
Rgenta's $20 million seed round in 2020 was co-led by Boehringer Ingelheim Venture Fund and Matrix Partners China, with Kaitai Capital and Legend Star Fund also investing. Martin Heidecker, head of Boehringer Ingelheim Venture Fund USA, chaired Rgenta's board at the time. The $52 million Series A in 2022 was led by AZ-CICC Healthcare Investment Fund, a fund started by AstraZeneca and CICC Capital. New money came from Korean Investment Partners and Delos Capital, alongside returning investors Lilly Asia Venture and Vivo Capital.
How the market is moving
AZ-CICC's managing director, Chen Bing, said his fund had been interested in the RNA-targeting field for some time before backing Rgenta. Lundbeck's head of research, Tarek Samad, said partnerships like the one with Rgenta let the company pursue gene targets it could not reach on its own. Both comments point to larger drugmakers looking outside their own labs for ways to drug RNA.
We wrote this summary from public statements by Rgenta Therapeutics and its investors. It is not investment advice.
Rgenta Therapeutics in the News
Leadership Team
Executive officers and directors listed on Rgenta Therapeutics's Form D filed Nov 3, 2026.
Earlier filings also listed Sun Linghao (director, last listed Feb 2022), Judith Li (director, last listed Feb 2022), Hongbo Lu (director, last listed Feb 2022), Fei Shen (director, last listed Feb 2022) and Martin Heidecker (director, last listed Mar 2021).
Sources
- SECRgenta Therapeutics, Inc. Form D, filed Feb 5, 2020
- SECRgenta Therapeutics, Inc. filing history
- CompanyRgenta Therapeutics team page
- CompanyRgenta Therapeutics about us page
- CompanyRgenta Therapeutics privacy policy
- CompanyRgenta Therapeutics news and press releases
- PressPR Newswire: Rgenta Therapeutics Enters into a Collaboration with Lundbeck